陕西中医2026，Vol.47Issue(1)：48-53,6.DOI:10.3969/j.issn.1000-7369.2026.01.008
藿苏养胃方联合XELOX化疗治疗晚期胃癌临床研究
Efficacy of Huosu Yangwei formula plus XELOX in advanced gastric cancer
摘要
Abstract
Objective:To investigate the clinical efficacy of Huosu Yangwei formula combined with XELOX chemotherapy in the treatment of advanced gastric cancer.Methods:Seventy patients with advanced gastric cancer meeting the inclusion criteria were selected and randomly divided into a control group(treated with XELOX chemo-therapy)and an experimental group(treated with Huosu Yangwei Formula combined with XELOX chemotherapy on the basis of the control group).After 2 cycles of intervention,the objective response rate(ORR),disease control rate(DCR),TCM symptom scores,TCM syndrome efficacy,Karnofsky Performance Status(KPS)scores and efficacy were compared between the two groups before and after treatment.Changes in serological indicators including hypox-ia-inducible factor-1α(HIF-1α),vascular endothelial growth factor(VEGF),matrix metalloproteinase-2(MMP-2),MMP-9,and immune function markers(CD4+,CD8+,CD4+/CD8+ratio)were also analyzed,as well as the inci-dence of chemotherapy-related adverse reactions.Results:No cases were lost to follow-up or missing in either group by the end of the study.After treatment,the ORR of the experimental group(14.3%)was higher than that of the control group(8.6%),but the difference was not statistically significant(P>0.05).The DCR of the experimental group(82.9%)was significantly higher than that of the control group(60.0%,P<0.05).Regarding TCM symp-toms,the experimental group had lower scores than the control group in fatigue,poor appetite,diarrhea with borbo-rygmus,postprandial fullness,epigastric distension and pain,and rough and dry skin,and the TCM syndrome efficacy was significantly superior to the control group(P<0.01).The KPS score of the experimental group increased com-pared with the control group(P<0.05),and the efficacy of KPS score was better than that of the control group(P<0.01).After treatment,the expression levels of HIF-1α,VEGF,MMP-2,and MMP-9 in the experimental group were significantly lower than those in the control group(P<0.01).Compared with the control group,the experi-mental group showed a significant increase in the proportions of CD4+cells and CD4+/CD8+ratio,and a significant decrease in CD8+cells after treatment(P<0.01).Certain chemotherapy-related adverse reactions occurred in both groups after treatment,but the incidence rates of nausea and vomiting,liver and kidney function impairment,consti-pation,fatigue,dry mouth,decreased appetite,and peripheral neurotoxicity in the experimental group were signifi-cantly lower than those in the control group(P<0.05).Conclusion:Huosu Yangwei Formula combined with XELOX chemotherapy can improve the clinical effective rate of advanced gastric cancer,alleviate patients'clinical symptoms,and reduce chemotherapy-related adverse reactions,thereby achieving a synergistic effect of reducing tox-icity and enhancing efficacy with chemotherapeutic drugs.关键词
晚期胃癌/藿苏养胃方/化疗/侵袭/转移Key words
Advanced Gastric cancer/Huosu Yangwei formula/Chemotherapy/Invasion/Metastasis分类
医药卫生引用本文复制引用
HAN Ming,ZHANG Nan,ZHENG Qinwei,FANG Shuangshuang,WANG Hongwei,NI Hongmei,FANG Shengquan..藿苏养胃方联合XELOX化疗治疗晚期胃癌临床研究[J].陕西中医,2026,47(1):48-53,6.基金项目
国家重点研发计划项目(2024YFC3505303) （2024YFC3505303）
国家自然科学基金青年科学基金资助项目(82505495) （82505495）
上海市进一步加快中医药传承创新发展三年行动计划项目(1-1-2) （1-1-2）
上海市级医院消化内科临床能力促进与提升专科联盟建设项目(SHDC22021311) （SHDC22021311）
上海中医药大学附属岳阳中西医结合医院大学科建设项目(QY71.42.02) （QY71.42.02）
上海中医药大学附属岳阳中西医结合医院中医专科建设项目[YW(2025-2026)-03-07] （2025-2026）
上海中医药大学科技发展项目(24KFL080) （24KFL080）
